Cargando…

Clinical development of CAR T cell therapy in China: 2020 update

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jianshu, Guo, Yelei, Wang, Yao, Wu, Zhiqiang, Bo, Jian, Zhang, Bin, Zhu, Jun, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115146/ https://www.ncbi.nlm.nih.gov/pubmed/32999455 http://dx.doi.org/10.1038/s41423-020-00555-x

Ejemplares similares

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
por: Yan, Xin, et al.
Publicado: (2022)

Target selection for CAR-T therapy
por: Wei, Jianshu, et al.
Publicado: (2019)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production
por: Guo, Yelei, et al.
Publicado: (2023)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
por: Guo, Yelei, et al.
Publicado: (2022)

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
por: Zhang, Yajing, et al.
Publicado: (2021)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
por: Wang, Yao, et al.
Publicado: (2018)

Inducing immunogenic cell death in immuno-oncological therapies
por: Ti, Dongdong, et al.
Publicado: (2022)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
por: Song, Yanjing, et al.
Publicado: (2017)

Mutant B2M‐HLA‐E and B2M‐HLA‐G fusion proteins protects universal chimeric antigen receptor‐modified T cells from allogeneic NK cell‐mediated lysis
por: Guo, Yelei, et al.
Publicado: (2021)

Neurological updates: neurological complications of CAR-T therapy
por: Tallantyre, Emma C., et al.
Publicado: (2020)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
por: Ivica, Nikola A., et al.
Publicado: (2021)

Infectious complications of CAR T-cell therapy: a clinical update
por: Stewart, Adam G., et al.
Publicado: (2021)

Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
por: Guo, Yelei, et al.
Publicado: (2017)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2022)

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
por: Wang, Zhenguang, et al.
Publicado: (2017)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2018)

Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
por: Crees, Zachary D., et al.
Publicado: (2021)

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
por: Feng, Kaichao, et al.
Publicado: (2017)

China enters CAR-T cell therapy era
por: Cao, Xin, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
por: Dai, Hanren, et al.
Publicado: (2020)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
por: Wei, Jianshu, et al.
Publicado: (2020)

Recent advances in CAR T-cell therapy for lymphoma in China
por: Che, Yuxuan, et al.
Publicado: (2023)

Clinical trials of CAR-T cells in China
por: Liu, Bingshan, et al.
Publicado: (2017)

New CAR Designs: Highlights From SOHO 2020
Publicado: (2021)

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
por: Pagotto, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_voe46ekaj1sgev7f2g1dn8e433